Wells Fargo Maintains Overweight on Viridian Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Overweight and raises the price target from $31 to $34.
Wells Fargo analyst Derek Archila maintains Viridian Therapeutics (NASDAQ:VRDN) with a Overweight and raises the price target from $31 to $34.